Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTI-003 in first-line recurrent or metastatic head and neck squamous cell carcinoma
2021-000055-39Phase 2Active
- Sponsor
- Immutep Limited
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing eftilagimod alpha + pembrolizumab with pembrolizumab alone (2 arms). Primary endpoint: Objective response rate. Started Jul 2021; status: active.
02
Drugs
eftilagimod alphapembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2021-000055-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000055-39.